EE9800323A - HIV proteaasi inhibiitorit VX 478 ja vees lahustuva vitamiin E derivaati vitamiin E-TPGSi sisaldavad preparaadid - Google Patents

HIV proteaasi inhibiitorit VX 478 ja vees lahustuva vitamiin E derivaati vitamiin E-TPGSi sisaldavad preparaadid

Info

Publication number
EE9800323A
EE9800323A EE9800323A EE9800323A EE9800323A EE 9800323 A EE9800323 A EE 9800323A EE 9800323 A EE9800323 A EE 9800323A EE 9800323 A EE9800323 A EE 9800323A EE 9800323 A EE9800323 A EE 9800323A
Authority
EE
Estonia
Prior art keywords
vitamin
tpgs
water
protease inhibitor
hiv protease
Prior art date
Application number
EE9800323A
Other languages
English (en)
Other versions
EE04093B1 (et
Inventor
Gary Tillman Lloyd
K. Roy Arup
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Priority claimed from US08/820,848 external-priority patent/US6730679B1/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority claimed from PCT/EP1997/001438 external-priority patent/WO1997035587A1/en
Publication of EE9800323A publication Critical patent/EE9800323A/et
Publication of EE04093B1 publication Critical patent/EE04093B1/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EE9800323A 1996-03-22 1997-03-21 HIV proteaasi inhibiitorit VX 478 ja vees lahustuva vitamiin E derivaati vitamiin E-TPGSi sisaldavad preparaadid EE04093B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations
US08/820,848 US6730679B1 (en) 1996-03-22 1997-03-20 Pharmaceutical formulations
PCT/EP1997/001438 WO1997035587A1 (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs

Publications (2)

Publication Number Publication Date
EE9800323A true EE9800323A (et) 1999-04-15
EE04093B1 EE04093B1 (et) 2003-08-15

Family

ID=27268205

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800323A EE04093B1 (et) 1996-03-22 1997-03-21 HIV proteaasi inhibiitorit VX 478 ja vees lahustuva vitamiin E derivaati vitamiin E-TPGSi sisaldavad preparaadid

Country Status (24)

Country Link
EP (1) EP0906107B1 (et)
CN (1) CN1225587A (et)
AP (1) AP1150A (et)
AT (1) ATE230602T1 (et)
AU (1) AU724239B2 (et)
BR (1) BR9708238A (et)
CA (1) CA2249336C (et)
CY (1) CY2444B1 (et)
CZ (1) CZ289958B6 (et)
DE (1) DE69718315T2 (et)
DK (1) DK0906107T3 (et)
EA (1) EA001484B1 (et)
EE (1) EE04093B1 (et)
ES (1) ES2190528T3 (et)
GE (1) GEP20012464B (et)
HK (1) HK1016896A1 (et)
IS (1) IS2066B (et)
NO (1) NO317639B1 (et)
NZ (1) NZ331645A (et)
RO (1) RO119923B1 (et)
SI (1) SI0906107T1 (et)
SK (1) SK284244B6 (et)
TR (1) TR199801881T2 (et)
UY (1) UY25926A1 (et)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114366808B (zh) * 2021-12-14 2023-10-13 南京农业大学 一种多糖和病毒抗原共递送纳米疫苗、其制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
CA2221145A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Also Published As

Publication number Publication date
SI0906107T1 (en) 2003-08-31
UY25926A1 (es) 2000-09-29
EE04093B1 (et) 2003-08-15
IS4840A (is) 1998-08-28
CA2249336C (en) 2005-11-22
DK0906107T3 (da) 2003-05-05
EP0906107B1 (en) 2003-01-08
GEP20012464B (en) 2001-06-25
AP1150A (en) 2003-03-14
ATE230602T1 (de) 2003-01-15
AU2159197A (en) 1997-10-17
EA001484B1 (ru) 2001-04-23
ES2190528T3 (es) 2003-08-01
NO984386D0 (no) 1998-09-21
NO984386L (no) 1998-11-20
AU724239B2 (en) 2000-09-14
CZ303598A3 (cs) 1999-03-17
TR199801881T2 (xx) 1999-01-18
BR9708238A (pt) 1999-08-03
SK126998A3 (en) 1999-10-08
EA199800755A1 (ru) 1999-06-24
CY2444B1 (en) 2004-11-12
NZ331645A (en) 2000-02-28
RO119923B1 (ro) 2005-06-30
IS2066B (is) 2005-11-15
EP0906107A1 (en) 1999-04-07
HK1016896A1 (en) 1999-11-12
CA2249336A1 (en) 1997-10-02
CZ289958B6 (cs) 2002-05-15
CN1225587A (zh) 1999-08-11
DE69718315T2 (de) 2003-10-30
DE69718315D1 (de) 2003-02-13
SK284244B6 (sk) 2004-12-01
AP9801343A0 (en) 1998-09-30
NO317639B1 (no) 2004-11-29

Similar Documents

Publication Publication Date Title
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
PT722439E (pt) Inibidores da protease de hiv
NO943511L (no) Farmasöytiske preparater og anvendelse derav
BR1100329A (pt) Composto e formulação farmacêutica
BR9500784A (pt) Composto e formulação farmacêutica
BR9504060A (pt) Composto e formulação farmacêutica
IT1266582B1 (it) Derivati (di)azacicloesanici e diazacicloeptanici
NO20011157L (no) Benzenderivater og farmasöytisk anvendelse derav
PT703954E (pt) Composicoes de derivados de polifenois e sua preparacao
CY2010013I1 (el) Ανοσογονες lhrh συνθεσεις και μεθοδοι που σχετιζονται με αυτες
MA26486A1 (fr) Aryl- et heteroaryl-thiazolocetohydrazides inhibiteurs de proteases, et compositions pharmaceutiques les contenant .
FI943100A (fi) Ansamysiinijohdannaisia antionkogeenisina ja syövänvastaisina aineina
PL328916A1 (en) Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs
DE69705628D1 (de) Chlorfluorkohlenwasserstoff freie aerosol-arzneizubereitungen enthaltend mometasonfuroat
DZ1926A1 (fr) Formulations pharmaceutiques.
TR199501429A2 (tr) Matriks metaloproteaz inhibitörlerinin yerine gecen 4-biarilpentanoik asitleri ve türevleri
EE9800323A (et) HIV proteaasi inhibiitorit VX 478 ja vees lahustuva vitamiin E derivaati vitamiin E-TPGSi sisaldavad preparaadid
DE29707628U1 (de) Präsentations- und Verkaufsregel
NO983556L (no) Formulering og anvendelse
BR1100596A (pt) Composto e formulações farmacêuticas
FI942785A0 (fi) 13,14-dihydro-PGF2beta ja sen isopropyyliesteri
ES1026536Y (es) Manguito de facil montaje y desmontaje.
BR1100293A (pt) Composto e composição farmacêutica
BR1100809A (pt) Composto e composição farmacêutica
BR1100838A (pt) Composto e composição farmacêutica

Legal Events

Date Code Title Description
LD4A Amendment in the specification
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231